$100 million Israeli fund makes first investment

The $100 million Israel Biotech Fund (IBF), founded to invest in Israeli bio-techs, has made its first investment in cancer treatment developer Vidac.  Vida’s VDA-1102 is the first ointment that selectively targets malignant skin cancer cells with minimal effects on surrounding healthy skin.


This entry was posted in Economy & Business. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *